Page results
-
A new CAR T-cell therapy developed by scientists at UCL has fewer ‘toxic’ side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase 1 clinical trial of patients at UCLH.
-
The National Paediatric Diabetes Audit (NPDA) is asking all children and young people (8-19 years) and parents/carers (of children under 8 years old) who have received diabetes care in the past 6 months, to fill in the survey.
-
A new scan could improve how millions of people with high blood pressure are treated, suggests a new study led by UCL and conducted at UCLH.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.
-
Having proton beam therapy: information for children aged 5-8 patient information page.
-
Having proton beam therapy: information for children aged 9-12 patient information
-
Having proton beam therapy: information for teenagers aged 13-17 patient information.
-
Patients with an aggressive form of leukaemia will now be able to receive a breakthrough immunotherapy on the NHS which was developed and trialled at UCLH and UCL.
-
On Sunday 23 November, the Royal National Orthopaedic Hospital (RNOH) successfully connected to UCLH’s Epic electronic health record (EHR). This is another milestone in our collaboration and digital transformation across North Central London.
File results
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0227 - Number of radiographers and nuclear medicine clinical scientists at Trust
-
FOI/2023/0220 - Internally produced patient information leaflets
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0224 - Patients prescribed medical equipment for use in the home
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment
-
FOI/2023/0226 - Treatment with Nivolumab
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0247 - Treatment guidelines for Idiopathic Pulmonary Fibrosis
-
FOI/2023/0244 - IT systems for digital dictation, speech recognition, outsourced transcription, video consultation and health information systems